IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.

@article{Oertel1993IBZMSPECTAP,
  title={IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.},
  author={Wolfgang Hermann Oertel and Johannes Schwarz and Klaus Tatsch and Guy Arnold and Thomas Gasser and Carl Martin Kirsch},
  journal={Advances in neurology},
  year={1993},
  volume={60},
  pages={519-24}
}
IBZM-SPECT is useful as a predictor for the responsiveness to oral L-DOPA therapy in de novo parkinsonian patients. A reduction of postsynaptic dopamine D2 receptors in de novo parkinsonian patients makes the diagnosis of Parkinson's disease rather unlikely. Normal IBZM binding does not prove the diagnosis of Parkinson's disease; however, together with a positive apomorphine test, it strongly supports the clinical diagnosis. At present the combination of IBZM-SPECT and apomorphine testing… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Parkinson DiseaseMay be treated byLevodopa
IBZM - SPECT is useful as a predictor for the responsiveness to oral L - DOPA therapy in de novo parkinsonian patients .
A reduction of postsynaptic dopamine D2 receptors in de novo parkinsonian patients makes the diagnosis of Parkinson 's disease rather unlikely .
A reduction of postsynaptic dopamine D2 receptors in de novo parkinsonian patients makes the diagnosis of Parkinson 's disease rather unlikely .
A reduction of postsynaptic dopamine D2 receptors in de novo parkinsonian patients makes the diagnosis of Parkinson 's disease rather unlikely .
All Topics